GYRE (Gyre Therapeutics) Interest Expense: $0.0 Mil (TTM As of Mar. 2026)


GYRE Gyre Therapeutics Inc GYRE
43 GF Score
Price $7.36
GF Value $9.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Interest Expense?

Gyre Therapeutics GYRE +12.58% 43 Interest Expense is $0.0 Mil as of Mar. 2026. GuruFocus rates GYRE with a GF Score™ of 43/100 and a GF Value™ of $9.81 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gyre Therapeutics's interest expense for the three months ended in Mar. 2026 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gyre Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -6.8 Mil. Gyre Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ 0.0 Mil. GuruFocus does not calculate Gyre Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gyre Therapeutics  (NAS:GYRE) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gyre Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-6.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.1 Mil.

Gyre Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Gyre Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Gyre Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Gyre Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Interest Expense Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.12 -0.04 0.00 0.00 0.00

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GYRE
43GF Score
Gyre Therapeutics Inc GYRE
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.0 Mil mean?
Gyre Therapeutics (GYRE) has a Interest Expense of $0.0 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Interest Expense too high?
Gyre Therapeutics' current Interest Expense is $0.0 Mil. Overall, Gyre Therapeutics has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Interest Expense compare to RLMD and ACRS?
Gyre Therapeutics' Interest Expense of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Interest Expense is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.81, compared to a current price of $7.36 — trading 25% below its estimated fair value. The current Interest Expense is $0.0 Mil. Gyre Therapeutics' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Interest Expense is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $7.36 is trading 25% below its estimated GF Value™ of $9.81. GuruFocus considers Gyre Therapeutics to be Modestly Undervalued.

Key valuation signals for GYRE:

  • Interest Expense: $0.0 Mil
  • GF Value™: $9.81 vs. price of $7.36 (25% below fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score

Get the complete analysis for GYRE

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$9.81
GF Value